Immuneering Corporation IMRX
3.73 USD +0.04 (+1.22%)
Nov 4, 2026, 11:07 AM EST
3.70 Day range 3.87
3.38 52-week range 8.48
- YTD
- -43.39%
- 1 year
- -41.61%
Financial health
Altman Z-Score
7.34 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
0 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B-3 / 5 overall
- DCF 4
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 4
Valuation
P/E -5.2×
FY 2019 5y median -3.9× FY 2025
P/S 0.0×
FY 2019 5y median 0.0× FY 2025
P/B 1.3×
FY 2019 5y median 1.6× FY 2025
P/FCF -6.4×
FY 2019 5y median -4.2× FY 2025
EV/EBITDA -3.0×
FY 2019 5y median -2.7× FY 2025
EV/Sales 0.0×
FY 2019 5y median 0.0× FY 2025
FCF Yield -15.7%
FY 2019 5y median -23.6% FY 2025
Profitability
Gross Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2019 5y median 0.0% FY 2025
ROE -25.6%
FY 2019 5y median -46.0% FY 2025
ROIC -26.7%
FY 2019 5y median -45.1% FY 2025
ROA -24.2%
FY 2019 5y median -41.3% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2019 FY 2025
Operating Income 7.3%
FY 2019 FY 2025
EPS (diluted) 37.7%
FY 2019 FY 2025
Free Cash Flow 17.4%
FY 2019 FY 2025
Financial Health
Current Ratio 17.5×
FY 2019 5y median 13.5× FY 2025
Quick Ratio 17.5×
FY 2019 5y median 13.5× FY 2025
Debt / Equity 0.0×
FY 2019 5y median 0.0× FY 2025
Net Debt / EBITDA 2.2×
FY 2019 5y median 1.3× FY 2025
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31